HSGX - Histogenics Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5485
+0.0309 (+5.97%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.5176
Open0.5200
Bid0.5501 x 3000
Ask0.5588 x 1400
Day's Range0.5200 - 0.5692
52 Week Range0.3750 - 3.3500
Volume2,631,740
Avg. Volume5,025,987
Market Cap34.021M
Beta (3Y Monthly)-0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.9500
Earnings DateMar 13, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.44
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Nov. 29, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.

  • GlobeNewswire23 days ago

    New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Cell therapy biotech Vericel eyes $2B knee repair market
    American City Business Journalslast month

    Cell therapy biotech Vericel eyes $2B knee repair market

    While a competitor stumbles, Cambridge-based cell therapy biotech Vericel Corp. recently saw its share hit a new high after the company announced that its knee cartilage regeneration product could help far more patients than originally thought.

  • Associated Presslast month

    Histogenics: 3Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...

  • GlobeNewswirelast month

    Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Nov. 01, 2018 -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain.

  • GlobeNewswire2 months ago

    Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018

    WALTHAM, Mass., Oct. 25, 2018 -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and.

  • ACCESSWIRE2 months ago

    What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price

    NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX) is a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. On September 5, 2018 HSGX announced that its Phase III clinical trial did not meet one of its primary endpoints, a measurement of pain and knee function after a year compared to microfracture surgery.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.

  • GlobeNewswire2 months ago

    Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. Canaccord Genuity LLC and BTIG, LLC acted as the joint book-running managers for the offering.

  • GlobeNewswire2 months ago

    Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant. The gross proceeds to Histogenics from this offering are expected to be $17.0 million, before deducting underwriting discounts and commissions, and offering expenses payable by Histogenics.  The warrants are exercisable immediately upon issuance at a price of $0.70 per share of common stock and have a term of five years commencing on the date of issuance. All of the securities in the offering are being sold by Histogenics.  Histogenics intends to use the net proceeds from the offering to complete the biologics license application submission relating to NeoCart, prepare for commercialization of NeoCart following approval by the U.S. Food and Drug Administration, if at all, and for general corporate purposes.

  • GlobeNewswire2 months ago

    Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants

    Histogenics Corporation (Histogenics) (HSGX), a leader in the development of restorative cell therapies, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  All of the securities in the offering are to be sold by Histogenics. Canaccord Genuity LLC and BTIG, LLC are acting as the joint book-running managers for the offering.

  • GlobeNewswire3 months ago

    Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

    WALTHAM, Mass., Sept. 26, 2018-- Histogenics Corporation, a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that the ...

  • Benzinga3 months ago

    Histogenics Slips Below $1 Threshold After Knee Cartilage Candidate Fails Late-Stage Study

    Histogenics Corp (NASDAQ: HSGX) shares were losing more than half their market value Wednesday following the release of top-line data from the Phase 3 trial of Neocart, its pipeline candidate to treat knee cartilage damage. Histogenics, a developer of restorative cell therapies, said Neocart did not meet the primary endpoint of statistically significant improvement in pain and function in a dual threshold responder analysis a year after treatment relative to microfracture. In the modified Intent to Treat population, which excludes patients randomized but not treated with Neocart, 74.2 percent showed clinically meaningful improvement in pain and function compared to 62 percent of microfracture patients at one year, which was deemed to be statistically insignificant.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of HSGX earnings conference call or presentation 9-Aug-18 12:30pm GMT

    Q2 2018 Histogenics Corp Earnings Call

  • Histogenics Sees Hammer Chart Pattern: Time to Buy?
    Zacks4 months ago

    Histogenics Sees Hammer Chart Pattern: Time to Buy?

    Histogenics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Associated Press4 months ago

    Histogenics: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 13 cents per share. Losses, adjusted for non-recurring gains, were 25 cents per share. The results missed Wall Street expectations. The average ...

  • ACCESSWIRE4 months ago

    Histogenics Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Histogenics Corp. (NASDAQ: HSGX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. ...